Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Nov;81(5):380-3.
doi: 10.1111/j.1600-0609.2008.01130.x. Epub 2008 Aug 6.

Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma

K F Wader  1 , U M Fagerli, R U Holt, B Stordal, M Børset, A Sundan, A Waage
Affiliations
Multicenter Study

Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma

K F Wader et al. Eur J Haematol. 2008 Nov.

Abstract

Objectives: Hepatocyte growth factor (HGF) is a potential key factor in multiple myeloma. Conversion of pro-HGF to its active form is a critical limiting step for its biological effects. We aimed to examine the levels of the most potent activator, the hepatocyte growth factor activator (HGFA), in serum and bone marrow plasma of patients with multiple myeloma.

Methods: The activated form of HGFA was measured by an enzyme-linked immunosorbent assay in serum (n = 49) and bone marrow plasma (n = 16) from multiple myeloma patients, and in serum from healthy controls (n = 24).

Results: The median concentrations of activated HGFA in myeloma and control sera were 39.7 (range 6.2-450.0) and 17.6 ng/mL (range 4.8-280.6), respectively. The difference was statistically significant (P = 0.037). The median concentration of activated HGFA in bone marrow plasma was 6.1 ng/mL (range 3.5-30.0).

Conclusion: We here show for the first time that the activated form of HGFA is present at high levels in serum and bone marrow of myeloma patients, thus providing a necessary prerequisite for the activation of HGF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serum concentrations of activated HGFA measured by ELISA in 49 multiple myeloma patients and 24 age- and gender-matched controls. Bars indicate median concentration.
Figure 2
Figure 2
Serum concentrations of HGF measured by ELISA in 49 myeloma patients and 20 age- and gender-matched controls. Bars indicate median concentration.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST. The hepatocyte growth factor/met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia. 2003;17:764–74. - PubMed
    1. Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A, Borset M. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica. 2005;90:479–88. - PubMed
    1. Holt RU, Fagerli UM, Baykov V, Ro TB, Hov H, Waage A, Sundan A, Borset M. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica. 2008;93:619–22. - PubMed
    1. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A. Hgf inhibits bmp-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 2007;109:3024–30. - PubMed
    1. Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Borset M. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in anbl-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res. 2004;10:6686–94. - PubMed

Publication types